SCHEMBL2017152

SCHEMBL2017152

CS(=O)(=O)Nc1ccc(-c2ccc(C=O)s2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 2/20 0.58
KIF11 P52732 4/20 0.47
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46
APP P05067 1/20 0.46
CYP2E1 P05181 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2A6 P11509 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2B6 P20813 1/20 0.43
CYP2C19 P33261 1/20 0.43
TP53 P04637 1/20 0.43
HDAC6 Q9UBN7 1/20 0.42
KEAP1 Q14145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2017041 0.79 PRF1 (0.56) PRF1APPCYP2E1CYP3A4CYP2A6
SCHEMBL32679340 0.76 APP (0.47) PRF1HPGDKDM4EHSD17B1HSD17B2
SCHEMBL14761123 0.75 PRF1 (1.00) PRF1
SCHEMBL14761121 0.75 PRF1 (1.00) PRF1
SCHEMBL14761124 0.75 PRF1 (1.00) PRF1
SCHEMBL9538845 0.74 APP (0.54) PRF1HPGDKDM4EALDH1A1HSD17B1
SCHEMBL28890682 0.74 APP (0.48) PRF1HPGDKDM4EALDH1A1APP
SCHEMBL31041151 0.73 KIF11 (0.79) KIF11HPGDKDM4EALDH1A1LMNA
SCHEMBL8809867 0.73 KIF11 (0.61) KIF11HPGDKDM4EALDH1A1LMNA
Lithium SCHEMBL31041154 0.71 KIF11 (0.76) KIF11HPGDKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2013-03-14 US disclosed
EP-2515903-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF Peter MacCallum Cancer Institute (AU) 2012-10-31 EP disclosed
WO-2011075784-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PRF1, GZMB, SERPINB1 PRF1 1/4885KIF11 3217/4885HPGD 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.